NEW YORK, Sept. 24, (GenomeWeb News) - Neurome announced today that it has entered into a research agreement with ImClone Systems in which Neurome will apply its proprietary technologies and expertise in quantitative neuropathology to assist ImClone Systems in the discovery of preclinical candidate molecules.
Already have a GenomeWeb or 360Dx account?Login Now.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.